The Origin of First‐in‐Class Drugs: Innovation Versus Clinical Benefit

Author:

Osipenko Leeza12ORCID,Potey Philippe3,Perez Bernardo14ORCID,Angelov Filip5ORCID,Parvanova Iva1ORCID,Ul‐Hasan Saba12ORCID,Mossialos Elias1ORCID

Affiliation:

1. Department of Health Policy LSE London UK

2. Consilium Scientific London UK

3. Queen's Medical Research Institute University of Edinburgh Edinburgh UK

4. Cleveland Clinic Cleveland Ohio USA

5. Department of Health Technology Technical University of Denmark Kongens Lyngby Denmark

Abstract

First‐in‐class (FIC) designation became a hallmark of innovation, however, even at the marketing authorization stage, little is known about the clinical benefits these products deliver. We identified the provenance of the FIC drugs that entered the French market from 2008 to 2018 and matched these medicines to the clinical benefit grading by Haute Autorité de Santé (HAS) and Prescrire. Analyses were performed using descriptive statistics to present our findings by drug origin and therapeutic area and to establish the degree of concordance between HAS and Prescrire. Of the 135 FIC drugs identified, 71.1% (n = 96) originated from the industry, 16.3% (n = 22) from academia, and 12.6% (n = 17) from joint partnerships. Three therapeutic areas accounted for most FIC medications: antineoplastic (25.9%, N = 35), anti‐infective (14.1%, N = 19), and metabolic (11.1%, N = 15) agents. HAS and Prescrire agreed on 60.74% of clinical benefit gradings. According to HAS, only 5% of all FIC drugs had substantial added benefit, and only 3%, according to Prescrire. HAS and Prescrire graded 45.9% and 68.2%, respectively, of FIC drugs as no clinical benefit and 48.9% and 28.9%, respectively, as some clinical benefit. FIC‐designated drugs are primarily of industry (> 70%) rather than academic origin. We found that 55% of FIC medicines that entered the French market over the 10‐year period deliver no additional clinical benefit. Whereas FIC medicines may represent important scientific advancements in drug development, in > 50% of cases, the new mode of action does not translate into additional clinical benefits for patients.

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference40 articles.

1. How innovative are new drugs launched in the UK? A retrospective study of new drugs listed in the British National Formulary (BNF) 2001–2012

2. Diagnosing the decline in pharmaceutical R&D efficiency

3. Improving Pharmaceutical Innovation By Building A More Comprehensive Database On Drug Development And Use

4. Added therapeutic benefit and drug licensing

5. How safe and innovative are first‐in‐class drugs approved by Health Canada: a cohort study. L'innocuité et l'aspect innovant des nouvelles classes de médicaments approuvés par Santé Canada: Une étude de cohorte. Healthc;Lexchin J.;Foreign Policy,2016

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3